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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival
that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and
HRQOL in a well-documented clinical cohort during their last two years of life.
Methods: In April 2015, we sent the Modified Medical Research Council Dyspnea Scale (MMRC), the modified
Edmonton Symptom Assessment Scale (ESAS) and a self-rating HRQOL questionnaire (RAND-36) to 300 IPF patients,
of which 247 (82%) responded. Thereafter, follow-up questionnaires were sent every six months for two years.
Results: Ninety-two patients died by August 2017. Among these patients, HRQOL was found to be considerably low
already two years before death. The most prominent declines in HRQOL occurred in physical function, vitality,
emotional role and social functioning (p < 0.001). The proportion of patients with MMRC scores ≥3 increased near
death. Breathlessness and fatigue were the most severe symptoms. Symptom severity for the following symptoms
increased significantly and reached the highest mean scores during the last six months of life (numeric rating scale/
standard deviation): breathlessness (7.1/2.8), tiredness (7.0/2.3), dry mouth (6.0/3.0), cough (5.8/2.9), and pain with
movement (5.0/3.5).
Conclusions: To our knowledge this is the first study demonstrating, that IPF patients experience remarkably low
HRQOL already two years before death, especially regarding physical role. In addition, they suffer from severe breathlessness
and fatigue. Furthermore, physical, social and emotional wellbeing deteriorate, and symptom burden increases near
death. Regular symptom and HRQOL measurements are essential to assess palliative care needs in patients with IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic disease
with high morbidity and poor survival [1–4]. It occurs
mainly in older adults, but the etiology of this progressive
disease is still unknown [1]. Although the disease trajec-
tory of IPF is variable, for many patients with IPF, survival
is worse than many common malignancies. This necessi-
tates early integration of palliative care to improve pa-
tients’ quality of life (QOL) and to relieve symptoms in
addition to disease-specific pharmacological treatment
and lung transplant assessment [5–9].
Existing studies have shown low health-related quality
of life (HRQOL) in IPF patients. However, only few of
them were prospective longitudinal studies, and most
were relatively small in terms of sample size or were
concentrated on pharmacological treatment [10–12]. IPF
patients have been shown to suffer from lower HRQOL
in real-life studies than in clinical studies [12, 13].
IPF patients suffer from many difficult symptoms, of
which breathlessness and cough are the most common
ones [8, 10, 14–20]. In addition, a substantial proportion of
patients report anxiety, depression and pain [10, 21–26].
Dyspnea is a major contributor to HRQOL, and de-
creased HRQOL is associated with higher mortality [27,
28]. In a prospective Australian longitudinal registry study,
impaired HRQOL was related to frequent respiratory
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hospitalizations and higher mortality [27]. However, to
our knowledge, no previous studies have reported changes
in HRQOL and symptom burden in connection with
forthcoming death.
This study aimed to investigate IPF patients’ HRQOL
and symptom burden during the last two years of life in
a prospective longitudinal follow-up study to recognise
needs for palliative care and end-of-life care planning
and to characterise their symptom burden in a unique
follow-up setting.
Materials and methods
Study population
The FinnishIPF study is a national prospective clinical
registry of IPF patients that was established in 2012. IPF
diagnosis is based on the ATS/ERS 2011/2015 criteria [1,
6]. Nearly all Finnish IPF patients are initially evaluated at
public university and central hospitals. Patients from these
specialist centres with informed consent are included in
the FinnishIPF registry, which consists of approximately
76% of all Finnish IPF patients [2]. Currently, the registry
contains data from over 700 IPF patients.
All 300 patients registered in the FinnishIPF study in
April 2015 were asked to participate in this substudy by
sending an informed consent form together with the
questionnaires. Those who did not respond within two
weeks were called and reminded. Of the 300 registered
patients, 247 (82%) provided informed consent for this
substudy, answered the first questionnaire and were in-
cluded in this study. Subsequently, the same question-
naire was sent to the patients five times at six months
intervals until August 2017.
Data collection and questionnaires
Disease and sociodemographic characteristics were col-
lected from patient records and with a separate ques-
tionnaire (Additional file 1). These included the date of
birth, sex, age, marital status, education, living condi-
tions, physical activity level, the need for assistance in
daily activities, the date of IPF diagnosis, smoking status,
and comorbidities. Patients were asked the frequency of
leisure time physical exercise that causes breathlessness
and sweating for a minimum 30min during the preced-
ing six months. Death certificates were acquired from
the “National Authority for Collecting and Compiling
Statistics on Various Fields of Society and Economy”.
The questionnaires regarding HRQOL and symptoms
were the RAND 36-Item Health Survey (RAND-36), the
Modified Medical Research Council Dyspnea Scale
(MMRC), and the modified Edmonton Symptom Assess-
ment Scale (ESAS).
RAND-36 [29] is a general QOL measurement tool with
existing Finnish general population reference values [30].
RAND-36 is similar to the previously IPF-validated
short-Form-36 [30–32]. RAND-36 is divided into eight
health concepts [29, 30]. Concepts are scored on a scale
from 1 to 100, where a lower score indicates a worse
HRQOL during the past four weeks [29, 30]. The concepts
are as follows: “general health” (five questions), “vitality”
(four questions regarding energy level and tiredness),
“bodily pain” (two questions), “physical functioning” (ten
questions regarding the ability to take care of personal hy-
giene and the ability to move and exercise), “physical role”
(four questions regarding role limitations due to physical
health), “mental health” (five questions regarding mood,
depression and anxiety), “emotional role” (three questions
regarding role limitations due to emotional problems),
and “social functioning” (two questions) [29, 30].
The self-rated MMRC measures the degree of disability
that breathlessness causes during day-to-day activities on
a scale from 0 to 4, in which 0 indicates no breathlessness
except during strenuous exercise, 1 indicates shortness of
breath when walking up a slight hill or hurrying on a level,
2 indicates walking slower than people of same age on a
level because of breathlessness or needing to stop to for
breath when walking at one’s own pace on a level, 3 indi-
cates needing to stop for breath after a few minutes when
walking on a level or after walking approximately 100m,
and 4 indicates that the patient is too breathless to leave
the house or is breathless when dressing or undressing
[33, 34].
The ESAS is a numeric self-rating symptom-based scale
that was originally developed to assess the symptoms of
cancer patients [35, 36]. Different symptoms are measured
on Numeric Rating Scale (NRS) from 0 (no symptoms) to
10 (the worst possible symptoms) [36–38]. In this study,
we used a version including 12 symptoms (pain at rest,
pain with movement, tiredness, nausea, depression, anx-
iety, insomnia, loss of appetite, shortness of breath, cough,
constipation, dry mouth, and overall wellbeing). There is a
lack of evidence to recommend cut-off points for the
ESAS. However, an NRS score ≥ 4 is commonly used as a
trigger for more comprehensive symptom assessment in
clinical practice [39].
Statistics and ethical aspects
The study population characteristics are presented as the
means with standard deviations (SD) or as counts with
percentages. Patients’ answers were grouped, according
the time they answered from the aspect of death. The
Kaplan-Meier method was used to estimate the cumula-
tive mortality after the diagnosis. We used restricted cubic
splines to detect a possible non-linear dependency. A non-
linear relationship between the RAND-36 domains, symp-
tom severity, the MMRC and time before death were
assessed by using 5-knot-restricted cubic spline
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random-effects regression models with appropriate distri-
bution and link functions. Models included age and gen-
der (only main effects) as covariates. A test of interaction
between independent variables was performed through
the MFPIgen command. The length of the distribution
(months before death) of knots was located at the 5th,
27.5, 50th, 72.5, and 95th percentiles, which correspond to
time before death of − 22, − 15, − 9, − 5 and − 1. The loca-
tions of the knots were determined by the percentiles rec-
ommended in Harrell’s publication [40].The normality of
the variables was tested by using the Shapiro-Wilk test.
The Finnish general population values for the eight
Rand-36 domains were weighted to match the gender and
age distribution of the study population, statistical analysis
between our population and general population was not
performed [30]. The Stata 15.0 [41] statistical package was
used for the analysis.
The ethics committee of Helsinki University Central
Hospital approved this study (381/13/03/01/2014). The
Finnish National Institute for Health and Welfare (Dnro
THL/1161/5.05.01/2012) approved the screening of hos-
pital registries for patients with IPF. All participating pa-
tients provided written informed consent to participate
to this specific study.
Results
Of the 247 patients included in the study 92 (37%) died
by August 2017 and were included in our follow-up co-
hort (Fig. 1).
The cumulative mortality of the patient cohort (n = 92)
is presented in Fig. 2. The median overall survival was 4.4
years (IQR 3.1–5.7). Patient characteristics are shown in
Table 1. A majority of the patients had comorbidities, of
which cardiovascular diseases were the most common
ones. None of the patients had lung cancer when entering
the study, but two patients were diagnosed with lung
cancer during the follow-up. Lung function measurements
within the last six months of life were available in only 28
(30%) of the patients (mean FVC 2.2 l (SD 0.6), 57%).
Antifibrotic medication was used by 33 (35%) of the
patients.
The proportion of the patients who could not perform
continuous moderate intensity physical exercise for at
least 30 min during the previous six months increased
from 34% 18–24months before death to 62% during the
last six months of life. Six months before death, 67% of
the patients reported needing assistance with their daily
activities, while 18–24 months before death this propor-
tion was 56%.
Health-related quality of life
Figure 3 shows the changes in the different dimensions
of HRQOL measured with RAND-36 during two years
Fig. 1 Flowchart of patient recruitment and response rate
Fig. 2 Cumulative mortality after the diagnosis of IPF. Time-point of
the diagnosis is marked with 0 and 95% confidence intervals with
the grey area. Kaplan-Meier method was used to estimate the
cumulative mortality
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before death. The decline in HRQOL was highly signifi-
cant in all dimensions except in physical role, which
showed very low scores by 24 months before death.
Symptoms
The intensity change of the symptoms measured by the
ESAS during the last two years of life is presented in
Fig. 4. The intensity of all symptoms except pain at rest
and insomnia increased significantly near death. During
the last six months of life, the mean NRS scores were as
follows: 7.1 (SD 2.8) for breathlessness, 7.0 (SD 2.3) for
tiredness, 6.0 (SD 2.5) for wellbeing, 6.0 (SD 3.0) for dry
mouth, 5.8 (SD 2.9) for cough, 5.0 (SD 3.5) for pain with
movement, 3.9 (SD 3.1) for insomnia, 3.9 (SD 2.9) for
anxiety, 3.8 (SD 2.9) for depression, 3.6 (SD 3.1) for con-
stipation, 3.4 (SD 3.3) for loss of appetite, 3.1 (SD 2.8)
for pain at rest and 1.8 (SD 2.5) for nausea.
The steep change in the proportion of patients with
MMRC scores ≥3 (needing to stop walking after approxi-
mately 100m or a few minutes because of breathlessness)
during the last two years of life is shown in Fig. 5.
Discussion
In this study, we demonstrate a rapidly increasing impair-
ment in HRQOL and escalating symptom burden in IPF
patients approaching death. Low HRQOL together with
severe breathlessness and fatigue were detected as early as
two years before death. In addition, several dimensions of
HRQOL declined further and the severity of many symp-
toms other than dyspnea increased during the last two
years of life.
In the present study, HRQOL was considerably im-
paired two years prior to death in IPF patients. Physical
role, i.e., role limitations due to physical health, was excep-
tionally low, but physical functioning, vitality and general
health appeared to be below the general population level
as well. Similar to our findings, an Australian registry
study of 516 IPF patients reported HRQOL impairments
in all domains, with the lowest score in activity, i.e., activ-
ities that cause or are limited by breathlessness [27]. The
importance of decreased HRQOL was further highlighted
in a recent study by Furukawa et al. that demonstrated
that low HRQOL was actually an independent prognostic
factor [28].
Although previous studies have demonstrated low
HRQOL in IPF patients [10–12], none of them focused
on the HRQOL from the aspect of approaching death in
a follow-up setting. The uniqueness of this study stems
from the continuing follow-up until death, and the sub-
sequent finding of a salient decline in HRQOL during
the last two years of life that was intensified near death.
Deterioration was identified in all domains except phys-
ical role, which was already remarkably low two years
before death. The most integral impairment was in phys-
ical, social and emotional functioning and vitality. In the
Australian registry study, approximately one-third (38%)
of the IPF patients experienced clinically important dif-
ferences in the decline of HRQOL during 12months
[27]. However, in that study, no HRQOL data was avail-
able from the period preceding death [27].
In lung cancer, functional concerns relating to physical
movement or functioning predominate patients’ symp-
tom burden throughout the disease course and have a
negative impact on HRQOL [42]. In addition, the sever-
ity of symptoms escalates, and the number of severe
symptoms increases during the last three months of life
[42–44]. A steep decline in HRQOL at the end-of-life is
Table 1 Patient characteristics
Total number of patients 92
Age, mean (range) 75 (57–92)
Males n (%) 67 (73)
Duration of IPF in years, mean (SD) 3.6 (2.3)
Education in years, mean (SD) 10 (3)
Living alone, n (%) 31 (34)
Working, n (%) 4 (4)
Smoking status, n (%)a
Smoker 6 (7)
Ex-smoker 50 (54)
Never-smoker 36 (39)
FVC (litres), mean (SD)b 2.9 (0.8)
FVC (% of predicted), mean (SD)b 78 (16)
Diffusion capacity, mean(SD)c 54 (13)
Co-morbiditiese, n (%)
Hypertension 41 (45)
Coronary heart disease 35 (38)
Diabetes 24 (26)
Heart failure 23 (25)
COPD 20 (22)
Cancer 16 (17)
Asthma 8 (9)
No co-morbidities 13 (14)
Number of co-morbidities, median (range) 2 (0–7)
Place of death, n (%)b
Hospitald 62 (67)
Home 19 (22)
Nursing home 4 (5)
Hospice 3 (3)
asmoking status, forced volume vital capacity (FVC) and diffusion capacity are recorded
at the time of diagnosis and other factors at the time of the first questionnaire
bData missing from 4 patients; c data missing from 12 patients; d10 in intensive care
unit; e patient-reported co-morbidities
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typical in patients dying of cancer compared with other
terminally ill patients [45, 46]. In COPD patients,
HRQOL gradually declines over time without a steeper
decline at the end-of-life [47]. Our data imply that pa-
tients with IPF experience gradual impairments in
HRQOL comparable to COPD patients but suffer from a
pronounced, rapid deterioration in HRQOL during the
last year of life, more closely resembling the disease tra-
jectory of cancer.
Our results corroborate earlier findings on dyspnea
and cough as the most severe symptoms in IPF patients
regardless of the disease phase [10, 21, 27, 48]. The in-
tensity of dyspnea increased during the follow-up, being
one of the most severe symptoms before death. In a
previous IPF registry study, dyspnea yielded the stron-
gest association with impaired HRQOL accounting for
71% of the variation in HRQOL [27]. In addition,
exertion dyspnoea measured by the MMRC has been
shown to correlate to HRQOL and symptom burden
[21, 49].
In addition to dyspnea, other activity-limiting symptoms
such as fatigue and pain in movement were among the
most severe symptoms in our study. These activity-limit-
ing symptoms can lead to physical inactivity and func-
tional impairment, triggering a vicious circle with worse
HRQOL. The intensity of depression and anxiety were,
however, relatively mild two years before death, although
these symptoms increased thereafter. In a recent study,
depression was an independent predictor for HRQOL im-
pairment, although it only accounted for 3.5% of the vari-
ation, whereas dyspnea accounted for 71% [27]. Our
results suggest that the relief of activity-limiting symptoms
together with psychosocial support may improve HRQOL
in advanced IPF.
Fig. 3 Relationships between Health-related quality of life domains (RAND-36) two years before death. The curves were derived from a 5-knot
restricted cubic splines regression models. The models were adjusted for age and gender. The grey area represents 95% confidence intervals.
Dashed lines mark Finnish general population levels
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As discussed above, patients with advanced IPF, COPD
and lung cancer suffer from a heavy symptom burden
and deteriorating HRQOL. This calls for comprehensive
symptom management and integrated palliative care
concomitant with disease-modifying therapies [21, 27,
47, 50–52]. Early integrated palliative care for patients
with lung cancer has shown substantial benefits, such as
lower depression scores, higher HRQOL, better commu-
nication of end-of-life care preferences, less aggressive
care at the end-of-life, and longer overall survival [51,
53]. Similarly, a randomised trial demonstrated better
control of dyspnea and a survival benefit with integrated
palliative care in patients with COPD and interstitial
lung disease [54]. In addition to cancer patients, early in-
tegrated palliative care may reduce end-of-life acute care
utilisation, and allow patients with IPF to die in their
preferred locations [55–58]. Integrated palliative care in
IPF patients seems to lower respiratory-related emer-
gency room visits and hospitalisations and may allow
more patients to die at home [55]. In this study, 67% of
patients died in hospital and 11% in intensive care,
which is in line with earlier findings, implying the
necessity of improvements in advanced care planning
and palliative care of patients with IPF [55, 59]. Our re-
sults provide insight into the most important needs of
end-stage IPF patients and support the use of
early-integrated palliative care, which should include
symptom control beyond treatment for dyspnea and psy-
chosocial support.
The relatively small study population limits our study,
as did not having systematic follow-up data on lung
function, which is at least partially due to the poor con-
ditions of many of our patients. Our study is to our
knowledge first to present follow-up data of HRQOL
and symptoms for over two years before death. The
strength is its real-life longitudinal design, with a unique
cohort of IPF patients approaching death with an out-
standing response rate, particularly considering the fact
that some of the patients were probably too weak to re-
spond during their final days or weeks of life. To our
knowledge, this is the first study describing comprehen-
sive patient-reported data on the HRQOL and symptom
burden of IPF patients from the perspective of ap-
proaching death.
Fig. 4 Relationships of symptom severity measured by ESAS two years before death. The curves were derived from a 5-knot restricted cubic
splines regression models. The models were adjusted for age and gender. Grey area represents 95% confidence intervals. ESAS, Edmonton
symptom assessment scale
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Conclusion
Patients with IPF suffer from exceptionally low HRQOL
together with severe breathlessness and fatigue already
two years before death. In addition, physical and
emotional wellbeing further deteriorates near death con-
currently with escalating overall symptom burden. In
clinical practice, structured measurements of HRQOL
and symptoms are necessary to guide high-quality
early-integrated palliative care and end-of-life planning
in IPF patients.
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